PTCTPTC Therapeutics, Inc.
$64.70+7.0% 1Y
$64.70
$57.8452 weeks$86.25
PTCT in its own filings
Nothing in PTCT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
274
Events found in the filings · across 1,328 filings · the record starts in 2013
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 21, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 15, 2013
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- SEC comment-letter activity23 occurrences
- 2025-09-24
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 21, 2026On September 21, 2026, the Company issued a press release announcing it completed the Acquisition. As previously disclosed, a rolling biologics license application (“BLA”) submission to the U.S. Food and Drug Administration for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.Regulation FD disclosure · Form 8-K
- Aug 28, 2026On August 25, 2026, PTC Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Sangamo Therapeutics, Inc. (“Sangamo”), pursuant to which the Company agreed to acquire from Sangamo, subject to the terms and conditions set forth in the Asset Purchase Agreement …Material agreement entered · Form 8-K
- Aug 13, 2026On August 12, 2026, the Company issued a press release in which it announced the planned Acquisition.Regulation FD disclosure · Form 8-K
- Jul 30, 2026On July 28, 2026, the Company appointed Hege Sollie-Zetlmayer to its board of directors (the “Board”), effective immediately, filling a vacancy on the Board.Earnings release · Form 8-K
- Jun 18, 2026On June 18, 2026, PTC Therapeutics, Inc. (the “Company”) completed its previously announced private offering of $550,000,000 aggregate principal amount of its 0.0% Convertible Senior Notes due 2031 (the “Notes”) and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee (the …Material agreement entered · Form 8-K
- Jun 16, 2026On June 15, 2026, PTC Therapeutics, Inc. (the “Company”) issued a press release announcing the pricing of its previously announced offering (the “Offering”) of $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031 (the “Notes”)Other event · Form 8-K
- Jun 9, 2026On June 8, 2026, Alethia Young, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board effective June 8, 2026.Director or officer change · Form 8-K
- May 7, 2026PTC Therapeutics Provides Corporate Update.Earnings release · press release
- Apr 28, 2026PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam.Regulation FD disclosure · press release
- Mar 25, 2026On March 24, 2026, PTC Therapeutics, Inc., (the “Company”) appointed Jessica Chutter to its board of directors (the “Board”), effective immediately, filling a vacancy on the Board.Director or officer change · Form 8-K
- Feb 19, 2026PTC Therapeutics Provides Corporate Update and.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…